Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 plus sintilimab and SOX as perioperative treatment for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
CTR20261105Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of arcotatug tavatecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by InnoCare Pharma. Started Apr 2026; status: active.
02
Drugs
arcotatug tavatecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20261105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261105.